Wegovy

Wegovy, a brand name for semaglutide, is a GLP-1 receptor agonist medication used for the treatment of obesity and weight management. Developed by Novo Nordisk, it has become newsworthy due to its increasing popularity and associated challenges. Several US states are dropping Medicaid coverage of GLP-1 drugs like Wegovy due to rising public spending. Simultaneously, the expiration of semaglutide patents in countries like India and China has led to the emergence of cheaper generic versions, raising concerns about potential misuse and accessibility. Studies suggest the drug's effectiveness varies based on individual factors like genetics, age, and sex. The rise of Wegovy and similar drugs is also impacting consumer behavior, such as reduced spending on groceries. Concerns are also growing about the use of Wegovy for purely aesthetic reasons, potentially contributing to unrealistic beauty standards and eating disorders.